Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: LUNG Clear all
Completed Phase 2 Interventional Results available

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

NCT00553800
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab, Erlotinib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
70 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Recruiting Phase 3 Interventional

Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features

NCT06946264
View directory record Official record
Conditions
Bronchiolitis, Bronchodilator Agents
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Sodium Chloride 0.9% Inhl 3Ml
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Months to 24 Months
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Terminated Phase 1 Interventional

Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer

NCT00707252
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Polyphenon E, Tarceva
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

NCT06981078
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Verekitug, Placebo
Drug · Other
Lead sponsor
Upstream Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
29
States / cities
Bakersfield, California • Encino, California • Lomita, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Completed Phase 1Phase 2 Interventional

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

NCT00066885
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
calcitriol + docetaxel
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
11
States / cities
Berkeley, California • Vallejo, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jul 22, 2026, 12:13 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Human Lung Responses to Respiratory Pathogens

NCT01967628
View directory record Official record
Conditions
Respiratory Infection
Interventions
Vitamin D3 (cholecalciferol), Placebo Sugar Pill
Dietary Supplement
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Jul 22, 2026, 12:13 AM EDT
Completed No phase listed Observational

Gastrointestinal Microbiome Influence on the Development of Bronchopulmonary Dysplasia

NCT03229967
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
16S rRNA stool microbiome sequencing.
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
0 Days to 7 Days
Enrollment
197 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 22, 2026, 12:13 AM EDT
Enrolling by invitation Not applicable Interventional

Centralized Lung Cancer Screening Engagement in At-Risk Populations

NCT07216144
View directory record Official record
Conditions
Lung Cancer Screening
Interventions
Centralized patient outreach for lung cancer screening
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 22, 2026, 12:13 AM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

NCT00823732
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment, management of therapy complications, assessment of therapy complications
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Jul 22, 2026, 12:13 AM EDT
Terminated Phase 2 Interventional Results available

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

NCT02093221
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 35 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 22, 2026, 12:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

NCT00482014
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
pemetrexed, cisplatin, carboplatin, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Jul 22, 2026, 12:13 AM EDT
Completed Not applicable Interventional Results available

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204
View directory record Official record
Conditions
Lung Diseases, Medication Compliance
Interventions
Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 22, 2026, 12:13 AM EDT
Withdrawn No phase listed Observational

Assessing Respiratory Variability During Mechanical Ventilation in Acute Lung Injury (ALI)

NCT01083355
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Jul 22, 2026, 12:13 AM EDT
Recruiting No phase listed Observational

Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma

NCT02241265
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 12:13 AM EDT
Terminated Phase 2 Interventional Results available

Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma

NCT02513667
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer
Interventions
Ceritinib, Stereotactic ablative body radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

NCT04367311
View directory record Official record
Conditions
Lung Cancer, NSCLC
Interventions
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Drug
Lead sponsor
Nasser Hanna
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults

NCT05386914
View directory record Official record
Conditions
Genetic Predisposition to Disease, Healthy Volunteers
Interventions
Sirolimus
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
45 Years to 65 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Not applicable Interventional Results available

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

NCT05092516
View directory record Official record
Conditions
Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Children's Respiratory and Environmental Workgroup

NCT03213184
View directory record Official record
Conditions
Asthma, Allergic Asthma, Allergies, Healthy
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
10
States / cities
Baltimore, Maryland • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Not yet recruiting Phase 1 Interventional

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

NCT07382726
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Adagrasib, Iza-bren
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 12:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 22, 2026, 12:13 AM EDT
Completed Phase 1 Interventional

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

NCT00130221
View directory record Official record
Conditions
Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions
2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap
Drug · Other
Lead sponsor
Cook County Health
Government
Eligibility
16 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 22, 2026, 12:13 AM EDT